Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) Research & Development (2016 - 2025)

AtriCure (ATRC) has disclosed Research & Development for 16 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 29.9% to $24.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $99.2 million, a 3.15% increase, with the full-year FY2025 number at $99.2 million, up 3.15% from a year prior.
  • Research & Development was $24.5 million for Q4 2025 at AtriCure, up from $22.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $35.0 million in Q4 2024 to a low of $11.2 million in Q1 2021.
  • A 5-year average of $18.8 million and a median of $18.6 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 68.09% in 2024, then fell 29.9% in 2025.
  • AtriCure's Research & Development stood at $13.8 million in 2021, then dropped by 0.43% to $13.7 million in 2022, then surged by 51.27% to $20.8 million in 2023, then surged by 68.09% to $35.0 million in 2024, then fell by 29.9% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Research & Development are $24.5 million (Q4 2025), $22.9 million (Q3 2025), and $29.3 million (Q2 2025).